BridgeBio Pharma, Inc. BBIO announced that it has dosed the first patient in the phase I/II ADventure study, which is evaluating its investigational adeno-associated virus (“AAV”) 5 gene therapy, BBP-631, for the treatment of patients with classic congenital adrenal hyperplasia (“CAH”), a group of genetic disorders that affect the adrenal glands.
Initial data from the study is expected in the second half of 2022.
The open-label phase I/II study will investigate the safety, tolerability and pharmacodynamic activity of BBP-631 in adults with classic CAH. The primary outcomes of the study are to check the safety, as well as change from baseline in endogenous cortisol levels.
Per the company, if successfully developed, BBP-631 will become the first treatment for CAH to restore the body’s hormone and steroid balance by helping people with the disease make their own cortisol and aldosterone.
Shares of BridgeBio have plunged 84.2% in the past year compared with the industry’s decrease of 32.6%.
Image Source: Zacks Investment Research
Apart from BBP-631, BridgeBio has an AAV9 gene therapy candidate, BBP-812, which is being developed for treating Canavan disease. In November 2021, the company dosed the first patient in a phase I/II study evaluating BBP-812 for treating Canavan disease. Initial data from the study is expected later in 2022.
Other promising pipeline candidates in BridgeBio’s portfolio include acoramidis, encaleret and infigratinib.
The company is evaluating its lead pipeline candidate, acoramidis, for the treatment of symptomatic transthyretin (“TTR”) amyloid cardiomyopathy (ATTR-CM). In December 2021, BridgeBio announced dismal top-line data from part A of a two-part ongoing phase III ATTRibute-CM study evaluating acoramidis for the given indication.
A phase IIb study is evaluating encaleret as a potential treatment for autosomal dominant hypocalcemia type 1 (ADH1), a rare form of hypoparathyroidism caused by mutations in the CASR gene. A phase II study is evaluating infigratinib in patients with achondroplasia, a form of dwarfism.
Zacks Rank & Stock to Consider
BridgeBio currently carries a Zacks Rank #4 (Sell).
Top-ranked stocks in the biotech sector include Codexis, Inc. CDXS, Cara Therapeutics, Inc. CARA and Alkermes plc ALKS, all sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Codexis’ loss per share estimates have narrowed 3.9% for 2022, over the past 60 days.
Codexis’ earnings have surpassed estimates in each of the trailing four quarters.
Cara Therapeutics’ loss per share estimates have narrowed 1.3% for 2022, over the past 60 days.
Cara Therapeutics’ earnings surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.
Alkermes’ earnings estimates have been revised 1.4% upward for 2022 over the past 60 days. The stock has increased 17% in the past year.
Alkermes’ earnings have surpassed estimates in each of the trailing four quarters.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How to Profit from Trillions on Spending for Infrastructure >>
Click to get this free report
Alkermes plc (ALKS): Free Stock Analysis Report
Codexis, Inc. (CDXS): Free Stock Analysis Report
Cara Therapeutics, Inc. (CARA): Free Stock Analysis Report
BridgeBio Pharma, Inc. (BBIO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
www.nasdaq.com